Tricyclic Full Agonists
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 8 2601
daemia: a seven year prospective angiographic study. Br. Med. J. 1984,
289, 220–223.
(17) Semple, G.; Skinner, P. J.; Gharbaoui, T.; Shin, Y.-J.; Jung, J.-K.;
Cherrier, M. C.; Webb, P. J.; Tamura, S. Y.; Boatman, P. D.; Sage,
C. R.; Schrader, T. O.; Chen, R.; Colletti, S. L.; Tata, J. R.; Water,
M. G.; Cheng, K.; Taggart, A. K.; Cai, T.-Q.; Carballo-Jane, E.; Behan,
D. T.; Connolly, D. T.; Richman, J. G. 3-(1H-Tetrazol-5-yl)-1,4,5,6-
tetrahydro-cyclocyclopentapyrazole (MK-0354): a partial agonist of
the nicotinic acid receptor, G-protein coupled receptor 109a, with
antilipolytic but no vasodilatory activity in mice. J. Med. Chem. 2008,
51, 5101–5108.
(18) (a) Benyo´, Z.; Gille, A.; Bennett, C. L.; Clausen, B. E.; Offermanns,
S. Nicotinic acid-induced flushing is mediated by activation of
epidermal langerhans cells. Mol. Pharmacol. 2006, 70, 1844–1849.
(b) Morrow, J. D.; Awad, J. A.; Oates, J. A.; Roberts, L. J., II.
Identification of skin as a major site of prostaglandin D2 release
following oral administration of niacin in humans. J. InVest. Dermatol.
1992, 98, 812–815.
(4) (a) Canner, P. L.; Berge, K. G.; Wenger, N. K.; Stamler, J.; Friedman,
L.; Prineas, R. J.; Friedewald, W. Fifteen year mortality in coronary
drug project patients: long-term benefit with niacin. J. Am. Coll.
Cardiol. 1986, 8, 1245–1255. (b) Pritzker, L. B. Do lipid lowering
drugs reduce the risk of coronary heart disease? Crit. ReV. Clin. Lab.
Sci. 1998, 35, 603–621. (c) Taylor, A. J.; Sullenberger, L. E.; Lee,
H. J.; Lee, J. K.; Grace, K. A. Arterial biology for the investigation
of the treatment effects of reducing cholesterol (ARBITER) 2.
Circulation 2004, 110, 3512–3517.
(5) McGovern, M. Niaspan: creating a new concept for raising HDL-
cholesterol. Eur. Heart J. Suppl. 2005, 7, F41-F47.
(6) Cheng, K.; Wu, T. J.; Wu, K. K.; Sturino, C.; Metters, K.; Gottesdiener,
K.; Wright, S. D.; Wang, Z.; O’Neill, G.; Lai, E.; Waters, M. G.
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic
acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci.
U.S.A. 2006, 103, 6682–6687.
(19) (a) Semple, G.; Boatman, P. D.; Richman, J. G. Recent progress in
the discovery of niacin receptor agonists. Curr. Opin. Drug DiscoVery
DeV. 2007, 10, 452–459. (b) Boatman, P. D.; Richman, J. G.; Semple,
G. Nicotinic acid receptor agonists. J. Med. Chem. 2008, 51, 7653–
7662.
(7) Pereira, J. N.; Holland, G. F.; Hochstein, F. A.; Gilgore, S.; Defelice,
S.; Pinson, R. The pharmacology of 5-(3-pyridyl)tetrazole, a hypoc-
holesteremic lipolysis inhibitor. J. Pharmacol. Exp. Ther. 1968, 162,
148–154.
(20) (a) Campbell, M.; Hatley, R. J.; Heer, J. P.; Mason, A. M.; Pinto,
I. L.; Rahman, S. S.; Smith, I. E. D. Chemical Compounds. Patent
WO 2005016867, 2005; GlaxoSmithKline. (b) Campbell, M.; Hatley,
R. J.; Heer, J. P.; Mason, A. M.; Nicholson, N. H.; Pinto, I. L.;
Rahman, S. S.; Smith, I. E. D. 2-Substituted Benzoic Acid Derivatives
as GPR109A Receptor Agonists. Patent WO 2005016870, 2005;
GlaxoSmithKline. (c) Pinto, I. L.; Rahman, S. S.; Nicholson, N. H.
Novel Compounds. Patent WO 2005077950, 2005; GlaxoSmithKline.
(d) Campbell, M.; Mason, A. M.; Pinto, I. L.; Pollard, D. R.; Smith,
I. E. D. Anthranilic Acid Derivatives and Their Use in Treatment of
Diseases of Lipid Metabolism, in Particular Dyslipidaemia. Patent WO
2006085108, 2006; GlaxoSmithKline. (e) Mason, A. M.; Pinto, I. L.;
Rahman, S. S. Anthranilic Acid Derivatives Active at the GPR109A
Teceptor. Patent WO 2006085111, 2006s; GlaxoSmithKline. (f)
Hatley, R. J.; Mason, A. M.; Pinto, I. L.; Smith, I. E. D. Anthranilic
Acid Derivatives as GPR109A Receptor Agonists. Patent WO
2006085112, 2006; GlaxoSmithKline. (g) Pinto, I. L.; Simpson, J. K.
Chemical Compounds. Patent WO 2006085113, 2006; GlaxoSmith-
Kline. (h) Hatley, R. J. D.; Pinto, I. L. Patent WO 2006/045564 A1,
2006. (i) Hatley, R. J. D.; Pinto, I. L. Xanthine Derivatives with
HM74A Receptor Activity. Patent WO 2006045565, 2006; Glaxo-
SmithKline. (j) Heer, J. P.; Smith, I. E. D. Xanthine Derivatives as
Selective HM74A Agonists Patent WO 2007017265, 2007; Glaxo-
SmithKline.
(21) (a) Boatman, D. P.; Schrader, T. O.; Semple, G.; Skinner, P. J.;
Jung, J.-K. Fused Pyrazole Derivatives and Methods of Treatment
of Metabolic-Related Disorders Thereof. Patent WO 2006069242,
2006; Arena. (b) Gharbaoui, T.; Skinner, P. J.; Shin, Y.-J.; Averbuj,
C.; Jung, J.-K.; Johnson, B. R.; Duong, T.; Decaire, M.; Uy, J.;
Cherrier, M. C.; Webb, P. J.; Tamura, S. Y.; Zou, N.; Rodriguez,
N.; Boatman, P. D.; Sage, C. R.; Lindstrom, A.; Xu, J.; Schrader,
T. O.; Chen, R.; Richman, J. G.; Connolly, D. T.; Colletti, S. L.;
Tata, J. R.; Semple, G. Agonist lead identification for the high
affinity niacin receptor GPR109a. Bioorg. Med. Chem. Lett. 2007,
17, 4914–4919. (c) Skinner, P. J.; Cherrier, M. C.; Webb, P. J.;
Shin, Y.-J.; Gharbaoui, T.; Lindstrom, A.; Hong, V.; Tamura, S. Y.;
Dang, H. T.; Chen, R.; Richman, J. G.; Connolly, D. T.; Semple,
G. Fluorinated pyrazole acids are agonists of the high affinity
niacin receptor GPR109a. Bioorg. Med. Chem. Lett. 2007, 17, 5620-
5623.
(22) (a) Semple, G.; Schrader, T.; Skinner, P. J.; Colletti, S. L.; Gharbaoui,
T.; Imbriglio, J. E.; Jung, J.-K.; Liang, R.; Raghavan, S.; Schmidt,
D.; Tata, J. R. A Preparation of Tetrazole Derivatives, Useful as
Modulators of RUP25 Receptor. Patent WO 2005044816, 2005; Arena
and Merck. (b) Colletti., S. L.; Beresis, R. T.; Chen, W.; Tata, J. R.;
Shen, H. C.; Marley, D. M.; Deng, Q.; Frie, J. L.; Ding, F. Niacin
Receptor Agonists, Compositions Containing Such Compounds and
Methods of Treatment. Patent WO 2006052555, 2006; Merck. (c)
Colletti, S. L.; Tata, J. R.; Shen, H. C.; Ding, F.-X.; Frie, J. L.;
Imbriglio, J. E.; Chen, W. Niacin Receptor Agonists, Compositions
Containing Such Compounds and Methods of Treatment. Patent WO
2006057922, 2006; Merck. (d) Raghavan, S.; Colletti, S. L.; Ding,
F.-X.; Shen, H.; Tata, J. R.; Lins, A. R.; Smenton, A. L.; Chen, W.;
Schmidt, D. Y.; Tria, G. S. Niacin Receptor Agonists, Compositions
Containing Such Compounds and Methods of Treatment. Patent WO
2006002557, 2006; Merck. (e) Colletti, S. L.; Shen, H.; Tata, J. R.;
Szymonifka, M. J. Niacin Receptor Agonists, Compositions Containing
Such Compounds and Methods of Treatment. Patent WO 2007027532,
2007; Merck. (f) Colletti, S. L.; Imbriglio, J. E.; Beresis, R. T.; Frie,
J. L. Niacin Receptor Agonists, Compositions Containing Such
Compounds and Methods of Treatment. Patent WO 2007035478, 2007;
Merck.
(8) Stuyt, P. M. J.; Kleinjans, H. A. J.; Stalenhoef, A. F. H. Tolerability
and effects of high doses acipimox as additional lipid-lowering therapy
in familial hypercholesterolemia. Neth. J. Med. 1998, 53, 228–233,
and references therein.
(9) Gundersen, K.; Demissianos, H. V. The Effects of 5-Methylpyrazole-
3-Carboxylic Acid (U-19,425) and Nicotinic Acid (NA) on Free Fatty
Acids (FFA), Triglycerides (TG) and Cholesterol in Man. In Drugs
Affecting Lipid Metabolism; Holmes, W. L., Carlson, L. A., Paoletti,
R., Eds.; Plenum Press: New York, 1969; pp 213-226 and references
therein.
(10) Eastwood, G. R.; Kellett, D. N. Some effects of 3-chloroisoxazole-
5-carboxylic acid on lipid and carbohydrate mechanism. Biochem.
Pharmacol. 1969, 18, 569–577, and references therein.
(11) (a) Larosa, J. C.; Miller, V. T.; Edwards, K. D. G.; DeBovis, M. R.;
Stoy, D. B. Acifran: a double-blind, randomized, placebo-controlled
efficacy study in type IIa hyperlipoproteinemic patients. Artery 1987,
14, 338–350, and references therein. (b) Jung, J.-K.; Johnson, B. R.;
Duong, T.; Decaire, M.; Uy, J.; Gharbaoui, T.; Boatman, P. D.; Sage,
C. R.; Chen, R.; Richman, J. G.; Connolly, D. T.; Semple, G.
Analogues of acifran: agonists of the high and low affinity niacin
receptors, GPR109a and GPR109b. J. Med. Chem. 2007, 50, 1445–
1448.
(12) Schaub, A.; Futterer, A.; Pfeffer, K. PUMA-G, an IFN-γ-inducible
gene in macrophages is a novel member of the seven transmembrane
spanning receptor superfamily. Eur. J. Immunol. 2001, 31, 3714–3725.
(13) (a) Wise, A.; Foord, S. M.; Fraser, N. J.; Barnes, A. A.; Elshourbagy,
N.; Eilert, M.; Ignar, D. M.; Murdock, P. R.; Steplewski, K.; Green,
A.; Brown, A. J.; Dowell, S. J.; Szekeres, P. G.; Hassall, D. G.;
Marshall, F. H.; Wilson, S.; Pike, N. B. Molecular identification of
high and low affinity receptors for nicotinic acid. J. Biol. Chem. 2003,
278, 9869–9874. (b) Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.;
Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA-G and HM74 are
receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat.
Med. 2003, 9, 352–355. (c) Offermanns, S. The nicotinic acid receptor
GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends
Pharmacol. Sci. 2006, 27, 384–390.
(14) (a) Karpe, F.; Frayn, K. N. The nicotinic acid receptor, a new
mechanism for an old drug. Lancet 2004, 363, 1892–1894. (b) Pike,
N. B.; Wise, A. Identification of a nicotinic acid receptor: Is this the
molecular target for the oldest lipid-lowering drug? Curr. Opin. InVest.
Drugs 2004, 5, 271–275.
(15) Benyo´, Z.; Gille, A.; Kero, J.; Csiky, M.; Sucha´nkova´, M. C.; Nu¨sing,
R.; Moers, A.; Pfeffer, K.; Offermanns, S. GPR109A (PUMA-G/
HM74A) mediates nicotinic acid-induced flushing. J. Clin. InVest.
2005, 115, 3634–3640.
(16) (a) Shen, H. C.; Szymonifka, M.; Deng, Q.; Carballo-Jane, E.; Cheng,
K.; Wu, K.; Wu, T.-J.; Wang, J.; Tong, X.; Ren, N.; Taggart, A.; Cai,
T.; Waters, G.; Hammond, M.; Tata, J. R.; Colletti, S. L. Discovery
of orally bioavailable and novel urea agonists for the high affinity
niacin receptor GPR109A. Bioorg. Med. Chem. Lett. 2007, 17, 6723–
6728. (b) Shen, H. C.; Ding, F.-X.; Taggart, A.; Cheng, K.; Carballo-
Jane, E.; Ren, N.; Chen, Q.; Wang, J.; Wolff, M.; Waters, G.;
Hammond, M.; Tata, J. R.; Colletti, S. L. Discovery of biaryl
anthranilides as full agonists for the high affinity niacin receptor.
J. Med. Chem. 2007, 50, 6303–6306. (c) Raghavan, S.; Tria, G. S.;
Shen, H. C.; Ding, F.-X.; Taggart, A. K. P.; Ren, N.; Wilsie, L. C.;
Krsmanovic, M. L.; Holt, T. G.; Wolff, M. S.; Waters, M. G.;
Hammond, M. L.; Tata, J. R.; Colletti, S. L. Tetrahydroanthranilic
acid as a surrogate for anthranilic acid: application to the discovery
of potent niacin receptor agonists. Bioorg. Med. Chem. Lett. 2008,
18, 3163–3167.